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Case presentation
An 18-year-old white male was admitted to the Clinical Research
Center of the Audie L. Murphy Memorial Veterans Hospital in San
Antonio for evaluation of magnesium repletion in Bartter's syndrome.
The diagnosis had been made at another hospital 5 years earlier when,
after being admitted for a urinary tract infection, the patient was found
to have hypokalemia and metabolic alkalosis with normal blood pres-
sure. Plasma renin activity was elevated (60 nglmllhr), and an angioten-
sin II infusion test failed to increase the diastolic blood pressure by 20
mm Hg until more than 30 to 40 times the normal dose was given. Renal
clearances under conditions of maximal free-water diuresis revealed
fractional distal solute reabsorption of .45, .54, and .52 (normal, .85—
.98). An open renal biopsy at the time of a ureteral implantation for right
vesicoureteral reflux showed marked hyperplasia and increased granu-
larity of the juxtaglomerular cells. The patient was given spironolac-
tone, ibuprofen, and potassium chloride; the serum potassium level
rose from 2.2 to 3.1 mEq/liter.
Because the patient was adopted at the age of 18 months, the family
history is not available. He has no limitations on his physical activities.
He has a learning impairment and goes to a special school, where he
does well. He reports that he feels fine but has symptoms such as
weakness, dizziness, and blurred vision when he forgets to take his
medicine.
The patient had been admitted to the Clinical Research Center on two
previous occasions. On the first admission the effect of chronically
administered indomethacin on fractional distal solute reabsorption was
evaluated. Values of .50 and .51 (not different from his control data)
were obtained. Eight months prior to the latest admission, he was
hospitalized for a study of the effect of a low chloride intake on
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fractional distal solute reabsorption. Values of .52, .60, and .57 ( a mean
of .56) were obtained at a time when his urinary chloride was below 10
mEq/day and when his plasma chloride was 84—88 mEq/liter. During
this same admission, he was given I to 4 mg/day of amiloride, a
potassium-sparing agent, for 4 days while ingesting a diet similar to that
regularly taken by the patient in his normal environment (sodium
chloride, 150 mEq/day, potassium 70 mEq/day). In this 4-day period,
his serum potassium rose from 2.9 to 3.3 mEq/liter. Three additional
days at home on 3 mg/day of amiloride did not increase the serum
potassium. His treatment regimen was restored to spironolactone, 75
mg/day; ibuprofen, 400 mg/day; and potassium chloride, 120 mEq/day;
therapy continued unchanged for the next 4 years. At times, the patient
has not complied with his treatment program.
During the latest admission, he entered the Clinical Research Center
for a short metabolic study to assess the effect of magnesium repletion
on potassium balance. He discontinued taking all medication except
potassium chloride 10 days before admission. On admission, the
laboratory data were as follows: sodium, 138 mEq/liter; potassium, 2.3
mEq/liter; chloride, 91 mEq/liter; and bicarbonate, 35 mEq/liter. The
BUN was 15 mg/dl; creatinine, 0.8 mg/dl; and glucose, 103 mg/dl. The
remainder of the SMA-12 was normal. Plasma magnesium was 1.2 mEq/
liter, with a normal range of 1.8 to 2.2 mEq/liter. The white blood cell
count was 10,300 mm3; hemoglobin, 15.8 g/dl; hematocrit, 46%; and
platelet count, 453,000 mm3. Urinalysis was normal.
The patient was given a constant diet containing 100 mEq of sodium,
25 mEq of magnesium, and 75 mEq of potassium per day. An additional
72 mEq/day of potassium chloride had to be given to maintain his serum
potassium above 2 mEq/liter. After a control period, an infusion of
magnesium chloride was given at the rate of 2 mEq/hour for 6 days.
Based on the dietary and urinary analyses, approximately 100 mEq of
magnesium was retained over the 6-day period. No feces were collect-
ed, so a complete balance study was not obtained. Plasma magnesium
rose from 1.0 to 2.1 mEq/liter. The plasma potassium rose from 2.3 to
2,6 mEq/liter with only a transient retention of 50 mEq of potassium on
the first day of infusion. Free-water clearance studies, performed the
day before the start of the magnesium infusions and the morning after
the end of the infusions, revealed fractional distal solute reabsorption of
.70 and .65 respectively. These data, although not in the normal range,
are higher than his data 4 years previously.
The patient was given his previous regimen of spironolactone,
ibuprofen, and potassium chloride and was discharged when his serum
potassium reached 3. 1 mEq/liter.
Discussion
DR. JAY H. STEIN (Chairman, Department of Medicine, and
Professor, The University of Texas Health Science Center, San
Antonio, Texas): Bartter's syndrome, first described in 1962 [1],
is characterized by hypokalemia, metabolic alkalosis, hyperren-
inemia, secondary hyperaldosteronism, and normal blood pres-
sure. Resistance to the pressor effects of angiotensin II and
norepinephnne also is characteristic. Histopathologic examina-
tion reveals hyperplasia of the juxtaglomerular complex. In
1976 Fichman [2], Verberckmoes [3], and Gill [4] demonstrated
increased production of urinary prostaglandin E2 in patients
with Bartter's syndrome. Further investigation disclosed that
the potent vasodilator PG!2 was increased in the blood vessels
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Fig. 1. A schema to explain the central findings in Banter's syndrome.
of patients with this syndrome, although measurement only of
the urinary metabolite 6 keto, PGF1, has been made [5].
Suppression of prostaglandin production with prostaglandin
synthetase inhibitors corrects all the chemical features of the
syndrome except the urinary potassium loss [4]; the serum
potassium usually increases towards but not to normal, reach-
ing levels of 3.0 to 3.4 mEq/liter, but large quantities of
potassium chloride typically still are required along with the
prostaglandin inhibitors.
If an obligatory renal loss of potassium is considered the
major abnormality in patients with Bartter's syndrome, the
sequence of events outlined in Figure 1 may serve to explain the
various components of the syndrome. According to this view,
the renal loss of potassium results in a decrease in the plasma
concentration of potassium, which has three further direct
sequelae—increased production of PGE2 by renal cells, in-
creased production of PGI2 by blood vessels, and decreased
production of aldosterone by the adrenals. The increase in
PGE2 stimulates renin production, which in turn results in
increased angiotensin II and stimulation of aldosterone produc-
tion by the adrenal gland. The actual level of plasma aldoster-
one concentration reflects the influence of two opposing forces:
stimulation of aldosterone production due to increased angio-
tensin II on the one hand and inhibition of aldosterone produc-
tion due to the hypokalemia on the other. An increase in renal
tubule kallikrein, consequent to the effects of both angiotensin
II and aldosterone, is possibly the cause of the observed
increase in plasma bradykinin. According to this schema, the
normal blood pressure values characteristic of patients with
Bartter's syndrome is the result of a balance between increased
pressor and depressor effects. The pressor influence of in-
creased angiotensin II is negated by the depressor effects of
both PG!2 and bradykinin. The interrelationships depicted in
Figure 1 should be regarded as a working hypothesis in which
some of the effects might not be the direct result of the indicated
stimuli.
Potassium loss and hypokalemia are common consequences
of many conditions including vomiting, diarrhea, and overuse of
diuretics or laxatives. Recently, a constellation of findings
suggestive of Bartter's syndrome was noted in infants ingesting
formulas low in chloride [6, 7]. When chloride deficits were
restored by administering either the sodium or potassium salt,
however, all the features of the syndrome disappeared [8].
Patients with cystic fibrosis lose excessive quantities of sodium,
potassium, and chloride in sweat and, early in their course,
some have been misdiagnosed as having Bartter's syndrome
[9]. These conditions can be differentiated from Bartter's syn-
drome and in each the associated potassium deficits can be
repaired readily.
If we exclude all conditions that resemble Bartter's syn-
drome, we are left with a large number of patients with
hypokalemia, metabolic alkalosis, renal potassium wasting, and
the other features of the syndrome, but with dissimilarities in
results obtained from careful studies of renal tubular function.
It appears that the basic renal defect(s) that leads to the
potassium wasting differs among patients who otherwise fullfill
all the criteria for having Bartter's syndrome.
Early reports indicated that a defect in proximal sodium
reabsorption was the fundamental disorder that ultimately
accounted for the excessive renal potassium loss [10—13]. In
recent years a defect in sodium and chloride reabsorption in the
thick ascending limb of the loop of Henle has been considered
as the "proximate" cause; this possibility was suggested by
Erkelens and Statius Van Eps [14] as well as by Kurtzman [15],
but was demonstrated by Chaimovitz [16], Fujita [17], and Gill
and Bartter [18]. Indeed, Dr. Bartter himself incorporated a
defect in sodium and chloride reabsorption in the thick ascend-
ing limb in his own definition of the syndrome, because renal
clearance studies demonstrated such a defect in the original
patient and in many subsequently described patients who
satisfied all his other criteria [19]. His definition depends on the
demonstration of a fractional distal solute reabsorption of less
than 0.65 obtained under conditions of maximal free-water
diuresis induced by the intravenous infusion of 5% dextrose in
water.
A number of investigators, however, have failed to demon-
strate this abnormality in some patients who, on the basis of
other findings, seem to have Bartter's syndrome. Moreover, a
recent preliminary publication has challenged the validity of
tests of renal diluting ability that use intravenous hypotonic
saline [20]. Kurtz et al have suggested that distal solute reab-
sorption is decreased during intravenous infusion of hypotonic
saline but is enhanced after oral water loading. Data showing
the effects of the oral and intravenous water loads in the same
patient are not available. Although this has not been the
experience of this laboratory, it should be emphasized that free-
water clearance studies may give variable results depending on
the volume status of the patient, the suppression of antidiuretic
hormone, and other important determinants of the parameters
measured.
In any case, certain questions remain to be clarified: Is
Bartter's syndrome the consequence of a single defect, or
rather the clinical phenotype of a variety of tubular defects? Is
the syndrome caused by a defect in sodium chloride transport
per se or by a primary potassium-wasting state? Are syndromes
associated with magnesium and calcium loss, as well as potassi-
um wasting, pathophysiologically linked?
In an effort to shed some light on these questions, I will
evaluate the data from some of the published cases of Bartter's
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syndrome and review some recent data acquired in the Clinical
Research Center at the Audie L. Murphy Memorial Veterans
Hospital and the University of Texas Health Science Center in
San Antonio. The cases I have selected from the literature are
those in which careful renal function studies were performed.
In proceeding through this analysis, I will consider the ways
in which Bartter's syndrome might relate to renal tubular
defects that produce the following: (1) potassium loss alone; (2)
potassium and sodium loss; (3 potassium and chloride loss; (4)
potassium and magnesium loss; (5) potassium and calcium loss;
and (6) potassium and hydrogen loss.
Most patients with Bartter's syndrome present with metabol-
ic alkalosis as well as hypokalemia [211. Urinary hydrogen loss
is promoted in several ways. These include increased aldoster-
one secretion, excessive delivery of sodium distally (where
sodium for potassium and hydrogen exchange occurs), or
possibly some consequence of hypokalemia per se. Because
metabolic alkalosis is a consistent finding in virtually all the
patients, I have chosen not to discuss it as a separate problem.
In the cases reviewed, as well as in our own studies, renal
tubular function was evaluated in patients and in control
subjects during diuresis induced by intravenous hypotonic
saline, by intravenous 5% dextrose in water, or by oral water
toads. I will utilize the following conventional definitions:
(1) Free water clearance: CH2O = V — Cosm, where V is mu
mm of urine excreted, and Cosm is the clearance of osmoles
(Uosm V/Sosm).
(2) Sodium delivery to the distal tubule: CH2O + CNa.
(3) Fractional distal solute reabsorption: CH20/(CH20 + CNa),
or CH2o/(CH20 + CNa+K), or CH20/(CH20 + Cc1).
Because estimates of fractional distal tubular solute reabsorp-
tion obtained by using CH2O and CNa alone err on the high side
when potassium is abundant in the urine, some investigators
have used clearances of CH2O and CNa+K (UNa+KV/SNa) to give
a more accurate value. Thus CNa+K is virtually equivalent to
C1 under these circumstances [181. Table 1 shows normal
values for these parameters of renal function.
Potassium loss
Excessive urinary potassium loss with its attendant hypoka-
lemia is regularly seen in states of endogenous overproduction
of sodium-retaining steroids (for example, primary aldosteron-
ism, dexamethasone-suppressible hyperaldosteronism) and
when steroids are exogenously administered (such as desoxy-
corticosterone). Because these conditions usually are associat-
ed with hypertension and hyporeninemia, they are easily differ-
entiated from Bartter's syndrome. The serum potassium returns
to normal after appropriate treatment in each case.
Excessive urinary potassium loss has been described, howev-
er, as the sole renal tubular defect in patients with all the other
features of Bartter's syndrome. The patient described by Norby
et al [22] had hypokalemia, normal plasma sodium and chloride
concentrations, and a renal biopsy that showed juxtaglomerular
hyperplasia. A balance study in this patient demonstrated
normal handling of sodium. Urinary aldosterone was 48 tg/day
(normal, less than 26) and plasma renin activity, 89 ng/ml
(normal, 1—5) at a time when the serum potassium was 2.5 mEq/
liter. Urinary osmolality fell to 37 mOsmlliter following an oral
water load, and free water was formed at a normal rate of 13.9
ml/min; the fractional distal solute reabsorption was 0.975.
Table 1. Water loads in normal subjects
Intra-
venous Intravenous
Mode: D5W hypo. NaCI
Oral
water
Uom (mOsm/liter) <100 <100
GFR (ml/min) 95—1 10 95—1 10
CH2O (mllmin) 6—12 6—13
CH2O + CNa (ml/min) 8—17 7—16
CH20/CH20 + CNa .80—.95 .65.80
CH20/CH2O + C1 .80-95 —
<100
95—110
5—11
6—14
.80—95
.80—92
Table 2. Potassium-losing patienta
Plasma K (mEq/liter)
Plasma HCO3 (mEq/liter)
Urinary K loss (mEq/day) by day 4
PRA-supine (nglml/hr)
Urinary aldosterone (pg/day)
All sensitivity (ng/kg/min)
NE" sensitivity (ng/kg/min)
Juxtaglomerular hyperplasia
Insulin tol. test (test for periodic paralysis)
Renal function tests (intravenous D5W)
Uosm (mOsm/liter)
GFR (mI/mm)
Co (mI/mm)
CH,O + CNa (mI/mm)
CH0/CH20 + CNa
2.7
29
25
18
9—23
36
60
neg.
neg.
112
146
10.5
13.1
0.80
a This patient also had hyperthyroidism.
b Norepinephrine.
Although the diagnosis of Bartter's syndrome seems convinc-
ing, there was no evidence for a proximal or distal tubule defect
in the handling of sodium.
We studied a patient with hypokalemia and hyperthyroidism
in our Clinical Research Center before treatment for thyroid
disease was begun. He had many of the features of Bartter's
syndrome (Table 2), but his fractional distal solute reabsorption
also was in the normal range (0.78 to 0.83). After treatment for
hyperthyroidism, he continued to waste potassium and main-
tained a plasma potassium in the range of 2.7 to 2.9 mEq/liter
despite a high potassium intake (over 120 mEq/day) and admin-
istration of triamterene. Plasma sodium and chloride concentra-
tions remained normal, and renal conservation of these ions
was normal. Therefore, the renal tubular defect in this patient
also appears to be in the handling of potassium alone.
Potassium and sodium loss
Urinary loss of both potassium and sodium has been found in
several patients considered to have Bartter's syndrome. Among
the early cases were those reported by Cannon et al [101 and
Arant Ct a! [lii. Cannon's patient demonstrated urinary sodium
excretion greater than intake during 15 days of sodium restric-
tion (Fig. 2). In addition, 4.4% of the filtered sodium was
excreted in the urine at a time when the patient was in
substantial negative sodium balance. Studies were not done to
locate the site of the tubular defect.
Tomko, Yeh, and Falls reported another patient with Bart-
ter's syndrome who demonstrated sodium, as well as potassi-
um, wasting [12]. When this patient's sodium intake was
reduced from 300 to 10 mEq/day, a marked negative sodium
balance continued through day four. The patient lost four
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Renal function studies (hypotonic saline)
Uosm (mOsm/liter) —
GFR (mI/mm) 116
CH2O (mI/mm) 12.5
CH2O + CNa
CH2O/CH2O + CN,
(mI/mm) 18
.73
Plasma K these patients did not corroborate a major role for increased
distal delivery.
Fujita et al administered hypotonic saline to a patient with the
classic features of Bartter's syndrome [17]. These investigators
Plasma HCO3 found fractional distal solute (sodium) reabsorption of 0.20 to
(mEq/l) 0.32 at a time when the distal delivery was normal (8 to 14 ml!
mm). They concluded that the patient had a defect in the
reabsorption of sodium in the ascending limb of the loop of
Henle and suggested that an accelerated sodium-for-potassium
exchange at the distal tubule might prevent "obligatory" sodi-
um loss and account for the maintenance of normal sodium
balance during sodium restriction.
Gill and Bartter published data obtained from 5 patients with
Bartter's syndrome and contrasted their findings with data from
5 patients with hypokalemia caused by psychogenic vomiting
[18]. The patients with psychogenic vomiting showed mean
distal fractional chloride reabsorption of 0.92 .04, whereas
the patients with Bartter's syndrome showed values of 0.49
.08. This low fractional distal chloride reabsorption in the
patients with Bartter's syndrome was not improved when the
patients were treated with prostaglandin synthetase inhibitors
even though many of the features of the syndrome were
restored to normal. These authors concluded that their findings
indicated a defect in sodium and chloride reabsorption in the
thick ascending limb of the loop of Henle and that this defect
was a separate and independent feature of the syndrome.
The patient under discussion today appears to share this
constellation of findings. He has all the features of Bartter's
syndrome including juxtaglomerular hyperplasia. Moreover, his
fractional distal solute reabsorption of 0.50 is in keeping with a
defect in sodium and chloride reabsorption in the ascending
limb of the loop of Henle.
It has been suggested that patients who take diuretics that
inhibit reabsorption of sodium and chloride in the loop of Henle
(such as furosemide) may manifest all the features of Bartter's
syndrome [24]. We have studied 2 patients who were self-
administering furosemide for more than 4 years, and I would
like to summarize our findings. The first patient was a 54-year-
old woman who had been admitted to the hospital emergency
room on four separate occasions because of cardiac arrest.
Each time she was found to be severely hypokalemic (serum
potassium concentration of 1.2 to 1.8 mEq/liter), and the
diagnosis of Bartter's syndrome was entertained. On admission
to our Clinical Research Center, her plasma potassium was
readily restored to normal within 4 days by the oral ingestion of
potassium chloride; this rapid and total repair is never possible
in patients with Bartter's syndrome. A water loading study
using 5% dextrose in water revealed a fractional distal chloride
reabsorption of 0.45. Each specimen obtained during the renal
clearance and during several selected days of "metabolic
Low Na intake Table 3. Potassium- and sodium-losing patienta
Plasma Na
(mEq/l)
K Supplement 500
(mEq/d) 250
K Excretion
(mEqld) 300
200
100
a From Ref. 12. The patient also had an increase in amino acids and
bicarbonate in the urine.
Fig. 2. Urinary sodium loss for 15 days in a patient with Banter's
syndrome and a potassium- and sodium-losing defect. (From Ref. 10).
pounds, developed symptomatic postural hypotension, and
required intravenous salt replacement. Free-water clearance
was 12.5 mI/mm, distal sodium delivery was 18 mllmin, and
fractional distal sodium reabsorption was 0.73 (Table 3). These
data suggest enhanced delivery of sodium from the proximal
tubule with normal reabsorption of sodium in the ascending
limb of the loop of Henle. The finding of increased urinary
amino acids and bicarbonate in this patient supports the hypoth-
esis that reabsorption in the proximal tubule was defective.
Chan studied a patient who showed an exceptionally elevated
delivery of sodium from the proximal tubule and a low fraction-
al distal sodium reabsorption during hypotonic saline infusion
[13]. He and his colleagues interpreted these data as being
indicative of a defect in proximal sodium reabsorption; the
resultant increase in distal delivery was held responsible for
decreasing fractional sodium reabsorption in the diluting
segment.
Potassium and chloride loss
In contrast to the sodium-losing tendency seen in a few
patients with Bartter's syndrome, most patients with the syn-
drome maintain sodium balance normally when intake is mark-
edly reduced. Results of renal function tests in patients in this
group are shown in Table 4. They have in common a low
fractional distal solute (sodium or chloride) reabsorption. Some
of the patients also exhibit a modest impairment in proximal
sodium reabsorption.
Chaimovitz and coworkers were the first to demonstrate
impaired sodium reabsorption in the ascending limb of the loop
of Henle in a patient with Bartter's syndrome [16]. The authors
stated that the patient had urinary salt loss, but they provided
no documentation of salt loss in the paper.
In 1974 Bartter et al published additional data from the 2
index cases published in 1962 [23]. In these 2 patients and in
another, the fractional distal sodium reabsorption ranged from
0.20 to 0.45 with distal deliveries of 8 to 16, 18 to 32, and 24 to
36 ml/min in the 3 patients, respectively. The values for distal
delivery in 2 of the patients suggested that they had a defect in
proximal sodium reabsorption as well, but further evaluation of
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Table 4. Potassium- and chloride-losing patients
References: [16] [231 [17] [18]
Mode:
Intravenous
hypo. NaCI
Intravenous
D5W
Intravenous
hypo. NaC1
Intravenous
D5W
U0,,
GFR
CH2O
CH2O + CN,
CH20ICH2O CNa
CH2O/CH2O + C1
No. of pts.
(mOsmlliter)
(mI/mm)
(mI/mm)
(mI/mm)
204
128
4.2
13.3
0.32
—
1
>100
40—100
'1—16
12—34
0.20-0.68
—
5
—
90
1.6—4.2
8—14
0.200.32
—
1
>100
30—110
6—8
10—35
0.20-0.65
5
balance" were subjected to analysis for diuretics. High concen-
trations of furosemide were found both on the day of the renal
clearance and on 3 other days (see Table 5).
The second patient had been taking daily doses of furosemide
for 4 years but, in contrast to the first, was doing so on the
advice of her physician. She had a plasma potassium of 2.3
mEq/liter on admission arid manifested all the other features of
Bartter's syndrome. She agreed to stop taking the furosemide
during the 2-week study period. Her plasma potassium was
readily restored to normal with small doses of potassium
chloride. Two water loading tests were done, one with intrave-
nous dextrose in water and the other with oral ingestion of
water. Fractional distal chloride reabsorption was 0.91 and
0.92. Thus, ascending limb function and potassium transport
were rapidly returned to normal following discontinuation of
furosemide.
Potassium and magnesium loss
Although hypomagnesemia is seen in about 20% of patients
considered to have Bartter's syndrome, few studies document
magnesium loss by balance techniques. Gitelman, Graham, and
Welt [25] studied 3 adults with muscle weakness attributed to
potassium deficiency, and a chronic dermatitis characterized by
thickening and a purple-red hue attributed to magnesium defi-
ciency. Two of the patients were sisters. All 3 had high urinary
aldosterone levels and elevated plasma renin activity. Urinary
potassium and magnesium loss was demonstrated by balance
techniques (Fig. 3, Table 6). Magnesium sulfate given intramus-
cularly resulted in magnesium retention. No effect was noted,
however, on the serum or urinary potassium. Spironolactone,
triamterene, and amiloride increased urinary excretion of sodi-
um and decreased urinary potassium but had no effect on
urinary magnesium. The authors concluded that the normal
mechanisms for distal sodium-for-potassium exchange were
operative but that magnesium was not being reabsorbed at this
site. In further studies, they showed that net reabsorption of
potassium occurred during periods of a low potassium intake
but that net secretion of potassium occurred during potassium
loading despite marked hypokalemia. Although renal biopsies
were not done, and sensitivity to infused pressor agents was not
evaluated, the patients did have normal blood pressure in the
presence of elevated plasma renin values, and Bartter's syn-
drome seemed to be the most likely diagnosis.
In an attempt to localize the renal defect in a patient with
Bartter's syndrome and hypomagnesemia, Baehler et a! per-
formed renal function tests during a diuresis induced by hypo-
Table 5. Furosemide abuse
Renal function studies:
Aa
i.v. D5W
Bb
iv. D5W
B
Oral
Uom (mOsm/liter) 144 50 40
GFR (mI/mm) 90 100 100
CH2O
CH20 + CNa
CH2O/CH20 + Ca
(mI/mm)
(mI/mm)
8.3
17.4
0.47
5.4
6.0
0.92
4.3
4.8
0.92
a Subject A took furosemide the day of the study. Urinary concentra-
tion was 82 mg/dl.
b Subject B had no furosemide for two weeks prior to this study.
tonic saline infusion [26]. They found diminished free-water
excretion and normal distal delivery of chloride with a low
fractional distal solute (chloride) reabsorption (Table 7). Mag-
nesium repletion with magnesium chloride resulted in potassi-
um retention and an increase in the fractional distal solute
reabsorption from 0,32 to 0.56. They concluded that the patient
had a defect in sodium and chloride reabsorption in the thick
ascending limb of the loop of Henle. Because magnesium is
believed to be absorbed in this segment of the tubule and since
"loop" diuretics (for example, furosemide) cause excessive
urinary excretion of magnesium, they believed it reasonable to
assign the defect to this segment of the tubule.
Potassium and calcium loss
Hypercalciuria occurs in some patients with hypokalemia and
elevated plasma renin activity [27]. Moreover, Michelakis dem-
onstrated that rerun release from renal tissue slices is enhanced
when the calcium concentration in the medium is increased
[28]. Only a few case reports have linked hypercalciuria with
Bartter's syndrome, however.
Fanconi et al reported 2 children with failure to thrive,
vasopressin-resistant polyuria, and hypercalciuria [29]. Over a
period of several years, both children developed hypokalemia,
metabolic alkalosis, hyperreninemia, and hyperaldosteronism.
Hypercalciuria persisted and nephroca!cinosis developed in one
of the patients. A renal biopsy, performed only in the patient
without nephrocalcinosis, revealed juxtaglomerular hyperpla-
sia. Fanconi suggested that the patients had congenital tubular
dysfunction with hypercalciuria and loss of concentrating abili-
ty from birth. The associated proximal tubular loss of sodium
could have resulted in a secondary stimulation of the juxtaglo-
merular apparatus and increased levels of renin and aldoster-
one. The hyperkaliuria and hypokalemia occurred much later in
these children and thus could have been the result of the
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6th day of Mg-deficient diet (1.0 mEq/day)
Subjects A B C Normals (4)
Serum (mEq/liter) 0.49" 0.62 0.77 1.22 .08
Urine (mEq/day) 4.25" 4.80 3.41 1.01 .21
a From [25].
b 4th day values; study terminated on fifth day.
Table 7. Potassium- and magnesium-losing patienta
Renal function studies (iv. hypotonic saline)
Control KCI MgCl
Uosm (mOsm/liter) 160 144 113
GFR (mI/mm) 105 91 83
CH2O (mI/mm) 2.9 3.8 6.1
CH2O + C, (mI/mm) 8.7 9.3 13.0
CH20/CH2O + C, 0.32 0.45 0.56
a From [261.
common expression of each of three well-defined functional
defects of the renal tubule. For convenience of description and
as a framework for discussion, I have designated these defects
as types I, II, and III.
Type I. This category comprises patients with a primary,
isolated, potassium transport defect. From our knowledge of
potassium handling by the renal tubule, it seems most likely that
this abnormality would reside in the distant portion of the distal
tubule and/or cortical collecting tubule. Sodium chloride trans-
port along the nephron is normal in this group of patients.
Type II. This category consists of patients with primary
defects in sodium chloride transport in multiple nephron seg-
ments. Salt wasting is prominent, and hypokalemia occurs as a
consequence of enhanced sodium-for-potassium exchange in
the distal tubule mediated by increased sodium delivery as well
as increased flow rate along this segment. Clearance studies in
patients with this variety of Bartter's syndrome demonstrate
both a proximal and a distal nephron defect. A defect in sodium
chloride transport in the thick ascending limb of the loop of
Henle would decrease medullary tonicity and lead to an in-
crease in tubular flow rate to the distal nephron. Salt wasting of
the magnitude described in these patients also might be due, in
part, to a sodium chloride transport abnormality in the collect-
ing duct.
Type 111. This category consists of patients with a localized
defect in sodium chloride transport in the thick ascending limb
of the loop of Henle. Such patients act as though they are
chronically taking furosemide. Distal solute reabsorption is
low, and potassium excretion—as in types I and Il—is exces-
sive. As in type II, the potassium wasting is due to enhanced
distal sodium-for-potassium exchange and a markedly in-
creased distal tubular flow rate. Decreased chloride reabsorp-
tion in the ascending limb would also diminish potassium
reabsorption in this segment and add to the kaliuresis.
I believe that the majority of patients with Bartter's syn-
drome who have sizable magnesium deficits also fall into this
category. Because magnesium is extensively reabsorbed along
the ascending limb, it would not be surprising if magnesium
deficiency were present in patients with the type-Ill defect.
Why magnesium deficits are not present to a clinically signifi-
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Fig. 3. Urinary potassium loss in a patient with Bartter's syndrome and
a potassium- and magnesium-losing defect, (From Ref. 25).
original tubular defect rather than the initiating events. In the
absence of renal function studies, the defect cannot be delineat-
ed further in these patients.
McCredie et al [301 described 4 children, whose gestation was
complicated by hydramnios, and who manifested failure to
thrive, vasopressin-resistant polyuria, urinary potassium loss,
hypercalciuria, and nephrocalcinosis. Intermittent hypokalemia
was also a common feature. These authors speculated that a
defect in proximal sodium and calcium reabsorption accounted
for their findings.
The group of patients with renal potassium and calcium loss
may have an entity quite separate from that of the other patients
I have reviewed. Given the presence of nephrocalcinosis in all
these patients, one wonders whether the site of abnormal
transport was in the distal nephron.
Comments
I have summarized the various clinical presentations and the
spectrum of renal functional abnormalities found in repre-
sentative cases of Bartter's syndrome reported in the literature
or evaluated at our Center. From this review, one can see that
this condition truly deserves its designation as a "syndrome."
Although all patients with Bartter's syndrome manifest the
same constellation of key findings (Fig. 1), these findings
appear to stem from severe and unrelenting hypokalemia rather
than from a specific renal tubular lesion. Based on the material
discussed, I propose that Bartter's syndrome might be the
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cant extent in all patients with Bartter' s syndrome is a subject
of investigation in our laboratory at present. The ability of
magnesium repletion to correct potassium wasting may have
nothing to do with a transport defect in the ascending limb but
rather may have to do with the well-known, nonspecific en-
hancement of potassium wasting by magnesium depletion.
Thus, the administration of magnesium in some manner might
diminish increased potassium secretion in the distal nephron.
In summary, I have attempted to subdivide patients with
Bartter's syndrome on the basis of the apparent site of the renal
transport defect. Although this classification scheme is based
on clearance measurements that are inherently imprecise and
on many assumptions that are open to question, I believe that
this scheme will serve as a stimulus for further investigations of
these fascinating patients.
Questions and answers
DR. FREDRIC COE (Renal Section, Mitchell Hospital, Chica-
go): Do you think the magnesium wasting in this patient arises
from a disorder in the thick ascending limb of the loop of Henle?
Is it possible that the magnesium wasting is part of a more
generalized disturbance of transport in that nephron segment?
DR. STEIN: As I mentioned, only 20% of patients with the
syndrome demonstrate hypomagnesemia. Because 65% of mag-
nesium is believed to be reabsorbed in the thick ascending limb
of the loop of Henle, only those patients with a demonstrated
defect in the thick ascending limb (type III) should demonstrate
a magnesium loss. This is true in the patient we are discussing
today, in Baehler's case [261, and in several of the patients
studied by Gill and Bartter [181. However, Gullner et al
described 3 siblings with hypokalemia and hypomagnesemia
who had normal fractional solute reabsorption in the distal
nephron (0.80 to 0.88) [31]. Other factors leading to magnesium
loss must be taken into consideration, including the degree of
volume expansion and whether extrarenal loss of magnesium
has occurred. How magnesium is handled throughout the renal
tubule is still unclear, and further research is required. When
we learn more about magnesium physiology, we may be able to
answer the questions about magnesium handling in the
syndrome.
DR. C0E: Do you think that furosemide or chlorothiazide
could be used as probes to determine a possible site for the
magnesium wasting? Magnesuria from furosemide administra-
tion might be less than in normal subjects if there already was a
transport disturbance in the thick ascending limb. Perhaps the
magnitude of the magnesuria in response to chiorothiazide
would be reduced if there were a disturbance in the cortical
portion of the thick ascending limb. Has there been any effort to
use these drugs as a means of localizing the transport disorder?
DR. STEIN: Zoccali and colleagues have attempted to study
the reabsorptive mechanisms in the syndrome with furosemide
and hydrochlorothiazide [32]. Using new techniques (as yet
untried by others), they concluded that the patients with the
syndrome have normal transport in the loop of Henle but a
striking impairment of distal tubular sodium transport. Because
both these diuretics acutely lower serum potassium, they are
dangerous agents to use in patients with already prominent
potassium deficiency.
DR. JORDAN J. COHEN: You were careful to point out how
cautious one must be in gauging distal reabsorption on the basis
of free-water clearance data. I assume that even greater caution
is warranted when osmolality is not maximally reduced. In
some of the cases you summarized, the urine osmolality was
not as low as one might have wished. How critically dependent
is the estimate of distal reabsorption on the degree of urinary
dilution achieved during water loading? Could sufficient artifact
be introduced to influence your proposed classification
scheme?
Da. STEIN: Your point is well taken. We do aim to achieve
hydration to a degree that would reduce urinary osmolality
below 100 mOsm/liter. However, patients with the defect in
sodium and chloride reabsorption in the thick ascending limb of
the loop of Henle regularly demonstrate an inability to reach
minimum urinary osmolality and defects in the production of
free water even in the presence of hydration greater than that
achieved in patients showing more efficient diluting ability [19].
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital,
Chicago): The rat colon can regulate net potassium flux [33] and
aldosterone receptors have been found in the rabbit colon [34].
Do patients with the primary distal potassium-wasting type of
Bartter's syndrome have defects in colonic potassium trans-
port? More specifically, are they able to conserve potassium
normally in the gastrointestinal tract?
DR. STEIN: That's a good question. The patient with primary
potassium loss studied by us and summarized in my discussion
had no evident diarrhea. Patients with diarrhea frequently have
efficient renal tubular mechanisms for retaining potassium.
However, Hager-Malecka et al described an infant with both
congenital nephropathy and chronic diarrhea with hypokalemic
alkalosis who lost sodium, chloride, and potassium from both
the kidneys and the gut [35]. Pasternack et al also found
potassium-losing nephropathy in 3 of 7 children with familial
chloride diarrhea [36].
DR. COHEN: If I understand correctly, you are hypothesizing
that the hyperreninemia and secondary hyperaldosteronism
characteristic of Bartter's syndrome are secondary to potassi-
um depletion and that this occurs whether or not associated
sodium or chloride or other deficits are present. I have two
questions: Is there a difference in the degree of hyperreninemia
and aldosteronism in instances of type I—pure potassium
wasting—as compared to the other types of Bartter's syndrome
you described? Is there any evidence that extrarenal potassium
wasting results in Bartter's syndrome?
DR. STEIN: Urinary potassium loss is the common pathway in
all of the three renal defects. We have not seen any striking
differences in the states of hyperreninemia among them, but I
would be surprised to be able to correlate the hyperreninemia
directly with potassium loss because so many other factors play
major roles in the control of renin release. Patients with
extrarenal potassium loss, particularly those with hypokalemia
due to laxative overuse, frequently show many of the markers
of the syndrome and have even been said to have "pseudo-
Bartter' s syndrome."
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pita!): The late Fred Bartter told me of a case of his syndrome in
which the potassium-losing defect was ameliorated by pregnan-
cy. One possible reason for this would be that higher progester-
one levels during gestation antagonize the excess aldosterone.
Can you speculate on any other physiologic (or hormonal)
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changes in pregnancy that might be beneficial to women with
Bartter's syndrome?
DR. STEIN: Few patients with Bartter's syndrome get better
during pregnancy. When pregnant, such patients must be
watched very closely with frequent monitoring of the serum
potassium and increased potassium intake. However, patients
with Liddle's syndrome, another hypokalemia-producing con-
dition that is characterized by excessive sodium retention, do
improve with pregnancy. This improvement is thought to be
due to increased progesterone production with pregnancy.
DR. KAI LAU (Renal Section, Michael Reese Hospital): Is it
possible that the metabolic alkalosis associated with Bartter's
syndrome plays a role in the potassium wasting on the one
hand, and in ameliorating the degree of magnesium wasting on
the other hand? We know that metabolic acidosis, by way of
contrast, has a significant magnesuric effect.
DR. STEIN: That is an interesting thought that has not been
adequately studied in these patients.
DR. GARY TOBACK (Renal Section, Mitchell Hospital): I had
the opportunity to care for a patient who was originally identi-
fied by Fred Bartter as having the syndrome and who visited
Dr. Bartter once a year from Chicago. The diagnosis was made
when the patient was in his 3Os. Although the disease usually is
clinically manifest early in life, it would appear that this man
developed the disease as an acquired syndrome, Can you
comment on how one might acquire Bartter's syndrome?
DR. STEIN: This syndrome, although most frequently seen in
children, has also been seen late in life. Whether it has always
been present without clinical manifestations or whether it
developed de novo as a result of some insult to the renal tubule
is not known. There is some evidence that an analogous
disorder can be acquired. Both gentamicin administration and
chemotherapy can lead to a similar picture 37]. It is difficult to
think of Baflter's syndrome as occurring only on an acquired
basis because it has been found in several members of families
in the same generation and across generations.
DR. COHEN: You have noted, as have others, that Bartter's
syndrome bears a striking resemblance to chronic furosemide
ingestion. This similarity suggests that some endogenous loop
diuretic may be circulating in patients with the syndrome. Is
there any evidence to support this notion? How would one look
for it?
DR. STEIN: There is no evidence for such an endogenous loop
diuretic. It would be difficult to look for it without some
knowledge of its chemical structure or its specific physiologic
property. It is, however, an intriguing thought.
DR. C0E: Do you have any information about urinary concen-
trating ability or tubular conservation of water as indices of the
function of the medullary portions of the thick ascending limb?
In particular, have such studies been performed when serum
potassium is normal and potassium deficiency has been
corrected?
DR. STEIN: It is difficult to do that study because complete
potassium repletion cannot be accomplished in patients with
Bartter's syndrome. These patients excrete all potassium ad-
ministered rapidly when repletion is attempted. Further, ii you
give them larger amounts of potassium chloride, sodium chlo-
ride excretion increases as well.
DR. JAMES BOURDEAU (Renal Section, Michael Reese Hospi-
tal): Is there any evidence to support an analogy between the
type-I, potassium-wasting, form of Bartter's syndrome and
amphotericin B nephrotoxicity, in which urinary potassium loss
is also seen?
DR. STEIN: Amphotericin toxicity is usually associated with
acidosis, of course, and therefore lacks total similarity. As I
mentioned, Bartter's syndrome can be produced by cytotoxic
drugs, which cause a nephropathy with features similar to those
in type I.
Da. BUSHINSKY: You downplayed the role of prostaglandins
in any of the three types of Bartter's syndrome, yet you
discharged your patient on a prostaglandin inhibitor. Do you
generally treat these patients with prostaglandin inhibitors?
Would you comment on the use of spironolactone, triamterene,
and amiloride in this condition?
DR. STEIN: Prostaglandin synthetase inhibitors do help re-
store the serum potassium toward normal but significant potas-
sium loss persists. I feel that the best therapy is large amounts
of potassium.
DR. SERAFINO GARELLA (Renal Section, Michael Reese
Hospital): I have two questions concerning type-I Bartter's
syndrome. You implied that potassium hypersecretion may be
the sole defect in these patients. In the presence of potassium
deficiency, aldosterone secretion appears to be decreased de-
spite the concurrent increase in renin secretion. How do you
account for the high levels of aldosterone secretion in these
patients? And what are your thoughts on the pathophysiologic
linkage between excessive urinary potassium losses and thick
ascending limb dysfunction?
DR. STEIN: Patients with Bartter's syndrome frequently have
plasma and urinary aldosterone values in the normal to low
range. However, these values are inappropriately high for the
prevailing state of potassium depletion. In response to your
second point, tubular reabsorption of sodium and chloride is not
necessarily decreased in patients with the primary potassium
loss. However, patients with a defect in sodium chloride
reabsorption in the thick ascending limb of the loop of Henle
produce the potassium loss in the following manner: The defect
in ascending limb transport diminishes medullary tonicity and
thus decreases water extraction from the descending limb. This
alteration increases the volume delivered to the ascending limb,
which is impermeable to water. Therefore, an exaggerated
volume will be delivered distally and will result in an increased
tubular flow rate. There will also be an increased distal sodium
delivery. Both the increased sodium delivery and tubular flow
rate will lead to increased potassium excretion. Further dimin-
ished potassium reabsorption in the ascending limb may
contribute.
DR. COHEN: If one were to imagine the antithesis of Bartter's
syndrome, one might envision the syndrome of hyporeninemic
hypoaldosteronism. Patients with hyporeninemic hypoaldoster-
onism are potassium retentive, they have hyperchloremia, and
they tend to be acidotic. Do you think this contrasting duality
might reflect some underlying continuum with a common
pathophysiology?
DR. STEIN: The disorders certainly must be considered
opposite ends of the spectrum of potassium defects. However, I
do not see any common pathophysiologic principle that can be
used to explain them totally.
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